JOP20210019A1 - شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل - Google Patents

شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل

Info

Publication number
JOP20210019A1
JOP20210019A1 JOP/2021/0019A JOP20210019A JOP20210019A1 JO P20210019 A1 JOP20210019 A1 JO P20210019A1 JO P20210019 A JOP20210019 A JO P20210019A JO P20210019 A1 JOP20210019 A1 JO P20210019A1
Authority
JO
Jordan
Prior art keywords
pharmaceutical dosage
disorders
dosage form
administered orally
modified release
Prior art date
Application number
JOP/2021/0019A
Other languages
English (en)
Inventor
Olenik Britta
Serno Peter
Lovis Kai
Tia Jacobs
KUSEL Julia
Lobback Carmen
Schirmer Heiko
Rubenbauer Philipp
Grossbach Danja
Stroyer Anke
Bierer Donald
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/043,567 external-priority patent/US10905667B2/en
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of JOP20210019A1 publication Critical patent/JOP20210019A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بأشكال جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل تشتمل على (3S)-3-(4-كلورو-3-{[(2S،3R) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانــوات صوديــوم وبعمليات لتحضير أشكال الجرعات هذه واستخدامها في معالجة و/أو الوقاية من أمراض، وبالتحديد في معالجة و/أو الوقاية من اضطرابات القلب، الكلى، الرئة والعيون واضطرابات الجهاز العصبي المركزي والاضطرابات الليفية والاضطرابات الالتهابية والاضطرابات الأيضية.
JOP/2021/0019A 2018-07-24 2019-07-19 شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل JOP20210019A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18185127 2018-07-24
US16/043,567 US10905667B2 (en) 2018-07-24 2018-07-24 Orally administrable modified-release pharmaceutical dosage form
PCT/EP2019/069561 WO2020020789A1 (de) 2018-07-24 2019-07-19 Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung

Publications (1)

Publication Number Publication Date
JOP20210019A1 true JOP20210019A1 (ar) 2021-01-24

Family

ID=67314781

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0019A JOP20210019A1 (ar) 2018-07-24 2019-07-19 شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل

Country Status (22)

Country Link
EP (1) EP3826627B1 (ar)
JP (1) JP2021532113A (ar)
KR (1) KR20210035235A (ar)
CN (1) CN112469402B (ar)
AU (1) AU2019311234A1 (ar)
BR (1) BR112020026644A2 (ar)
CA (1) CA3107169A1 (ar)
CL (1) CL2021000160A1 (ar)
CO (1) CO2021000450A2 (ar)
CR (1) CR20210043A (ar)
DO (1) DOP2021000015A (ar)
EC (1) ECSP21003707A (ar)
IL (1) IL280083A (ar)
JO (1) JOP20210019A1 (ar)
MA (1) MA53368A (ar)
MX (1) MX2021000904A (ar)
PE (1) PE20210415A1 (ar)
PH (1) PH12021550170A1 (ar)
SG (1) SG11202100369WA (ar)
TW (1) TW202019402A (ar)
UY (1) UY38308A (ar)
WO (1) WO2020020789A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245342A1 (en) 2019-06-07 2020-12-10 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
TW202412753A (zh) 2022-06-09 2024-04-01 德商拜耳廠股份有限公司 用於治療女性心臟衰竭合併保留射出分率的可溶性鳥苷酸環化酶活化劑

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
EP0277092B1 (de) 1987-01-14 1992-01-29 Ciba-Geigy Ag Therapeutisches System für schwerlösliche Wirkstoffe
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN103097387B (zh) 2010-07-09 2016-11-02 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) * 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
MX2020005646A (es) 2017-12-01 2020-08-20 Bayer Pharma AG Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico.

Also Published As

Publication number Publication date
UY38308A (es) 2020-02-28
DOP2021000015A (es) 2021-02-15
ECSP21003707A (es) 2021-02-26
EP3826627A1 (de) 2021-06-02
MA53368A (fr) 2021-06-02
PH12021550170A1 (en) 2021-09-13
TW202019402A (zh) 2020-06-01
CA3107169A1 (en) 2020-01-30
AU2019311234A1 (en) 2021-02-04
CN112469402A (zh) 2021-03-09
IL280083A (en) 2021-03-01
CR20210043A (es) 2021-03-09
JP2021532113A (ja) 2021-11-25
EP3826627B1 (de) 2023-10-18
PE20210415A1 (es) 2021-03-04
SG11202100369WA (en) 2021-02-25
WO2020020789A1 (de) 2020-01-30
BR112020026644A2 (pt) 2021-03-23
MX2021000904A (es) 2021-03-31
KR20210035235A (ko) 2021-03-31
CL2021000160A1 (es) 2021-06-04
CO2021000450A2 (es) 2021-01-29
CN112469402B (zh) 2024-05-14
EP3826627C0 (de) 2023-10-18

Similar Documents

Publication Publication Date Title
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release
PH12018500162A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MX2021002321A (es) Nuevos metodos.
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
EA202190334A1 (ru) Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением
PH12021551541A1 (en) Compositions and methods for treating neurodegenerative disorders
MX2016016480A (es) Nuevos usos terapeuticos de derivados de bencilidenguanidina para el tratamiento de proteopatias.
MX2021002322A (es) Nuevos metodos.
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
MX2017005299A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2019014675A (es) Solucion de levodopa para infusion.
CA3156118A1 (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CYCLOBENZAPRINE